COVID-19 antibody levels and related factors study
Website / Documentation
A longitudinal study of COVID-19 antibody levels pre and post COVID-19 vaccination and related factors
We are running a longitudinal study measuring COVID-19 infection status and the level of anti-SARS-CoV-2 antibodies in staff at a clinical trials unit in London. This study aims to help understanding of how different factors impact the level of anti-SARS-CoV-2 antibodies a person has.
We will compare antibody levels pre and post COVID-19 vaccination and compare the difference between individuals who were previously infected with SARS-CoV-2 with those who have not been infected. We will also compare the antibody levels between different vaccines, the first and second dose, and people with and without concomitant diseases, especially those who are on immunosuppressants. We also want to collect data on adverse events for each vaccine type.
The data collected will contribute to understanding what relationship there may be between anti-SARS-CoV-2 antibody levels and vaccination side effects experienced, vaccine type, previous COVID-19 infection and severity of symptoms, susceptibility to re-infection, age, ethnicity, and concomitant medication.
For information on the demographics of the staff population and data we have gathered so far visit: https://www.richmondresearchinstitute.org/covid-19/testing
- Raising capital
What we need help with
We are seeking funding to support the cost of the study. Richmond Research Institute is a not-for-profit organisation dependent on external funding. The results of the study will be published in scientific journals and on the Richmond Research Institute website.
Best way to get in touch
- In Progress